Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease
Recommended Citation
Rammo R, Rock A, Transou A, Raghunathan A, and Rock J. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease. J Neurosurg 2016; 124(2):496-500.
Document Type
Article
Publication Date
2-1-2016
Publication Title
Journal of neurosurgery
Abstract
Meningiomas are common intracranial tumors categorized as Grades I-III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.
Medical Subject Headings
Adult; Antineoplastic Agents, Hormonal; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Meningioma; Neoplasm Recurrence, Local; Octreotide; Treatment Outcome
PubMed ID
26274993
Volume
124
Issue
2
First Page
496
Last Page
500